The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. In fulfilling that task, OOPD evaluates scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. The office also works on rare disease issues with the medical and research communities, professional organizations, academia, governmental agencies, industry, and rare disease patient groups.Continue reading
Category Archives: Resource Library
Understanding the Medical Device Tax
Ernst and Young Technical Line: Implementing the medical device excise tax Continue reading
Bioeconomy Report Released at BIO 2012
Battelle/BIO State Bioscience Industry Development Report Released at the BIO 2012 INternational Convention.
Significant levels of research and development in bioscience industries continuously drive innovation and new product development.Continue reading
Flagship Biosciences finds Arizona a great home for serving pathology digitally
Flagship Biosciences, a fast growing pharmaceutical services company based in Flagstaff, AZ, is a leading example of the power of the collaborative nature of the Arizona bioindustry.Continue reading
Beware of Trademark Scams
Many trademark applicants are getting official looking notices from scam artists. These notices make it appear that the notice is from the United States Patent and Trademark Office. Unless carefully examined these notices can fool just about anyone.Continue reading
E&Y 2012 Report: Progressions, The third place: health care everywhere
Disruptive innovations and unsustainable costs propel life sciences companies into the behavioral change business
The full potential of personalized medicine requires both medical and behavioral scienceContinue reading
Find high quality clinical research sites in Arizona with ASU CONECTR
ASU CONECTR, an established network of high quality clinical research sites in Arizona, assists organizations in the placement and conduct of clinical trials. Committed to excellence in clinical research processes, CONECTR sites have a track record of rapid study start-up, faster contract and regulatory turnaround times, and successful patient enrollment. For more information about CONECTR, go to www.conectr.org .Continue reading
The Next Steps After SBIR/STTR Reauthorization
This year, technology and business organizations, including AZBio worked together with Congress to reauthorize the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) program. Sean Greene, Associate Administrator for Investment and Special Advisor for Innovation at the U.S. Small Business Administration, has recently shared his thoughts on what comes next on the SBA Community Blog…Continue reading
Opportunity Alert: Resources and Support for Going Global
The Arizona Commerce Authority (ACA) has recently launched Arizona’s State Trade and Export Promotion (STEP) initiative funded by the US Small Business Administration and ACA.Continue reading
The Biosciences – Advancing Arizona’s economy and health in the 21st century
Arizona’s Bioscience Sector is Blooming. View online or download the updated presentation that leaders of Arizona’s bioscience industry are using statewide. Continue reading